{"url_path":"/sec/pbyi/8-k/2026-06-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1401667/0001437749-26-020793-index.html","accession_number":"0001437749-26-020793","cik":"0001401667","ticker":"PBYI","issuer_name":"PUMA BIOTECHNOLOGY, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1401667/0001437749-26-020793-index.html","primary_entity_key":"0001401667","primary_entity_name":"PUMA BIOTECHNOLOGY, INC."},"word_count":374,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\n \n\n(a)\n\nPuma Biotechnology, Inc., a Delaware corporation (the “Company”) held the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 11, 2026 at the Company’s principal executive offices, 10880 Wilshire Blvd., Suite 1700, Los Angeles, California.\n\n \n\n \n\n(b)\n\nThe following proposals were voted upon at the 2026 Annual Meeting, and the final voting results with respect to each such proposal are set forth below:\n\n \n\n**Proposal 1:**\n\nThe Company’s stockholders elected the eight nominated directors identified below, each to serve and to hold office for a one-year term until the close of the Company’s next annual meeting of stockholders in 2027 and until their successors have been duly elected and qualified or until their earlier resignation or removal.\n\n \n\n**Nominee**\n\n**For**\n\n**Withheld**\n\n**Broker**\n\n**Non-Votes**\n\nAlan H. Auerbach\n\n37,130,678\n\n785,624\n\n6,064,713\n\nAlessandra Cesano\n\n37,472,173\n\n444,129\n\n6,064,713\n\nAllison Dorval\n\n37,447,432\n\n468,870\n\n6,064,713\n\nMichael P. Miller\n\n37,220,974\n\n695,328\n\n6,064,713\n\nJay M. Moyes\n\n36,586,798\n\n1,329,504\n\n6,064,713\n\nAdrian M. Senderowicz\n\n37,217,253\n\n699,049\n\n6,064,713\n\nBrian Stuglik\n\n37,372,588\n\n543,714\n\n6,064,713\n\nTroy E. Wilson\n\n32,546,955\n\n5,369,347\n\n6,064,713\n\n \n\n**Proposal 2:**\n\nThe Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026.\n\n \n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker**\n\n**Non-Votes**\n\n42,612,940\n\n1,328,476\n\n39,599\n\n0\n\n \n\n**Proposal 3:**\n\nThe Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers.\n\n \n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker**\n\n**Non-Votes**\n\n29,326,673\n\n7,878,580\n\n711,049\n\n0\n\n \n\n**Proposal 4:**\n\nThe Company’s stockholders did not approve an amendment to the terms of the warrant, issued to Alan H. Auerbach, President and Chief Executive Officer of the Company on October 4, 2011, as amended on June 15, 2021, to purchase 2,116,250 shares of the Company’s common stock at $16.00 per share (the “Auerbach Warrant”), to extend the term of the Auerbach Warrant from October 4, 2026 until October 4, 2028.\n\n \n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker**\n\n**Non-Votes**\n\n18,234,150\n\n19,596,238\n\n85,914\n\n0\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nPUMA BIOTECHNOLOGY, INC.\n\n \n\n \n\n \n\n \n\n \n\nDate: June 16, 2026\n\nBy:\n\n/s/ Alan H. Auerbach\n\n \n\n \n\n \n\nAlan H. Auerbach\n\n \n\n \n\n \n\nChief Executive Officer and President"}